Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neoadjuvant Chemotherapy
100%
Mucinous Adenocarcinoma
100%
Extracellular mucin
100%
Esophageal Adenocarcinoma
83%
Tumor Area
50%
Mucinous
50%
Surgery Alone
33%
Validation Cohort
33%
Confidence Interval
16%
Chemotherapy
16%
Overall Survival
16%
Patient Survival
16%
Hazard Ratio
16%
Poor Survival
16%
Resection Specimen
16%
Adenocarcinoma
16%
Small Bowel Adenocarcinoma
16%
Pharmacokinetic Interaction
16%
Histological Subtypes
16%
Clinical Impact
16%
Phase III Clinical Trial
16%
Material Analysis
16%
Biological Interactions
16%
Biochemical Interactions
16%
Histological Phenotype
16%
Medicine and Dentistry
Mucin
100%
Neoadjuvant Chemotherapy
100%
Post-Hoc Analysis
100%
Mucinous Carcinoma
100%
Esophageal Adenocarcinoma
83%
Neoplasm
50%
Overall Survival
16%
Cancer
16%
Adenocarcinoma
16%
Clinical Trial
16%
Hazard Ratio
16%
Pharmacokinetics
16%
Gastrointestinal Carcinoma
16%
Nursing and Health Professions
Mucin
100%
Post Hoc Analysis
100%
Neoadjuvant Chemotherapy
100%
Colloid Carcinoma
100%
Esophageal Adenocarcinoma
83%
Neoplasm
50%
Confidence Interval
16%
Overall Survival
16%
Hazard Ratio
16%
Adenocarcinoma
16%
Gastrointestinal Carcinoma
16%
INIS
patients
100%
chemotherapy
100%
esophagus
100%
adenocarcinomas
100%
surgery
36%
tumors
27%
validation
18%
cancer
9%
comparative evaluations
9%
clinical trials
9%
phenotype
9%
hazards
9%
interactions
9%
Biochemistry, Genetics and Molecular Biology
Mucin
100%
Clinical Trial
16%
Overall Survival
16%
Pharmacokinetics
16%